In this presentation, Anand A. Patel, MD, reviewed the contemporary standard-of-care treatment roadmap for AML in 2025, covering key phases like induction chemotherapy (eg, the “7+3” regimen), consolidation…
Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, New York, discusses the treatment strategies for patients who develop secondary acute myeloid leukemia (AML) following hypomethylating agent…
NEW YORK (Reuters Health) – Parenteral hydration offers virtually no benefit to hospice patients with advanced cancer. There are no established standards for hydration at the end of…
NEW YORK (Reuters Health) – While oxybutynin is often used prophylactically to reduce irritative urinary symptoms related to intravesical bacillus Calmette-Guerin (BCG) therapy for bladder cancer, it actually…
NEW YORK (Reuters Health) – In patients with liver cancer related to hepatitis B virus (HBV) infection, giving nucleoside analogues after curative surgery appears to reduce the risk…
NEW YORK (Reuters Health) – Patients with myelodysplastic syndrome (MDS) who are treated with azacitidine before allogeneic stem-cell transplantation fare as well as patients receiving standard pre-transplant induction chemotherapy, according to a French…
NEW YORK (Reuters Health) – Reduced-intensity conditioning that includes two daily 2.5-mg/kg doses of antithymocyte globulin before allogeneic stem-cell transplantation for hematologic malignancy significantly reduces graft-versus-host disease (GvHD)…
NEW YORK (Reuters Health) – Patients with myelodysplastic syndrome (MDS) who are treated with azacitidine before allogeneic stem-cell transplantation fare as well as patients receiving standard pre-transplant induction…
One of the most common dietary supplements taken by many American adults is a daily multivitamin. Recently, a new study found that men over 50 who took a…
NEW YORK (Reuters Health) – Even the best strategies for selectively testing colorectal CRC tumors for mismatch repair (MMR) gene mutations will miss 5% to 15% of Lynch…
NEW YORK (Reuters Health) – The use of tumor necrosis factor alpha inhibitors (TNF-I) therapy for various immune-mediated chronic inflammatory diseases does not increase the risk of cancer,…
NEW YORK (Reuters Health) – Two independent studies have shown that long-term outcomes are better with radiotherapy and chemotherapy rather than radiotherapy alone in patients with anaplastic oligodendrogliomas…
